Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Fate Therapeutics Inc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 139 | 2 | 143 | +6 |
| Shares | 79.7M | 31.4K | 80.6M | +958.2K (+1.2%) |
| Value | $88.9M | $35.0K | $101.6M | +$12.7M (+14.2%) |
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (23)
Institutions that held Fate Therapeutics Inc at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wilshire Advisors LLC | 8,486,822 | $10.7M | 27.71% |
| Quadrature Capital Ltd | 377,357 | $475.5K | 0.01% |
| Knott David M Jr | 365,000 | $459.9K | 0.19% |
| Man Group plc | 219,658 | $276.8K | 0.00% |
| Deutsche Bank AG | 157,159 | $198.0K | 0.00% |
| Atom Investors LP | 110,231 | $138.9K | 0.01% |
| Algert Global LLC | 106,920 | $134.7K | 0.00% |
| Los Angeles Capital Management LLC | 95,185 | $119.9K | 0.00% |
| Torrey Growth & Income Advisors | 67,522 | $85.1K | 0.03% |
| HRT Financial LP | 60,877 | $76.0K | 0.00% |
| Creative Planning | 26,294 | $33.1K | 0.00% |
| R Squared Ltd | 17,929 | $22.6K | 0.01% |
| Mercer Global Advisors Inc | 16,377 | $20.6K | 0.00% |
| CIBC Bancorp USA Inc. | 11,593 | $14.6K | 0.00% |
| Westmount Partners, LLC | 10,098 | $12.6K | 0.00% |
| Osborne Partners Capital Management, LLC | 10,000 | $12.6K | 0.00% |
| SRS Capital Advisors, Inc. | 8,570 | $10.8K | 0.00% |
| CX Institutional | 2,817 | $4.00K | 0.00% |
| Federated Hermes, Inc. | 3,015 | $3.80K | 0.00% |
| Group One Trading, L.P. | 2,831 | $3.57K | 0.00% |
| Caitlin John, LLC | 40 | $50 | 0.00% |
| Turning Point Benefit Group, Inc. | 14 | $17 | 0.00% |
| Cloud Capital Management, LLC | 32 | $0 | 0.00% |
Sold out (17)
Institutions that held Fate Therapeutics Inc at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Baker Bros. Advisors LP | 2,485,018 | $2.78M |
| Cubist Systematic Strategies, LLC | 111,512 | $124.9K |
| Virtu Financial LLC | 100,879 | $113.0K |
| MetLife Investment Management | 67,990 | $76.1K |
| Headlands Technologies LLC | 49,556 | $55.5K |
| Manufacturers Life Insurance Company, The | 41,134 | $46.1K |
| Simplex Trading, LLC | 38,019 | $42.0K |
| CI Private Wealth, LLC | 29,724 | $33.3K |
| State Board of Administration of Florida Retirement System | 28,016 | $31.4K |
| Point72 (DIFC) Ltd | 10,465 | $11.7K |
| Franklin Resources Inc | 10,197 | $11.4K |
| Financial Engines Advisors L.L.C. | 10,072 | $11.2K |
| Raymond James Financial Inc | 1,450 | $1.62K |
| Toronto Dominion Bank | 850 | $952 |
| Fortitude Family Office, LLC | 391 | $438 |
| Twin Peaks Wealth Advisors, LLC | 200 | $187 |
| Point72 Asia (Singapore) Pte. Ltd. | 50 | $56 |
Not filed for Q3 2025 yet (2)
Institutions that held Fate Therapeutics Inc at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Grassi Investment Management | 18,000 | $20.0K |
| CIBC World Markets Corp | 13,400 | $15.0K |